THE TAPE

Definium Therapeutics, Inc. Common Shares

$30.16▼ −5.99%
Last close
Relative strength
51RS
of 99, against every stock
Unconfirmed
+47.0%
six months against the S&P 500
211-session range
−39.3%
from the high
$14.62$49.70
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
No US GAAP filings to read.
Why it is on no screen

DFTX is off the screens on 3 checks.

A base has formed14.2 weeks, from 30.05 to 49.70.
Long enough to count14.2 weeks against 3 needed.
Shallow enough39.5% deep against 35% allowed.
Close to its pivot-39.3% from the pivot; listed down to -20%.
Relative strengthRS 51 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
$25.04
-17.0% · tested 3× · last 107 sessions ago
Resistance above
$32.16
+6.6% · tested 3× · last 10 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

Definium Therapeutics, Inc. Common Shares is not on any of the screens right now. Its relative strength rating is 51, and it sits in Medicinal Chemicals & Botanical Products.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against the S&P 500
-3.1%
Three months against the S&P 500
-32.3%
Six months against the S&P 500
+47.0%

Its industry has too few members to make an index of, so it is read against the S&P 500 and can only be turning, caution or unconfirmed.

Peers
Same industry
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 3.7% either way across its last 4 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business

No figures in US GAAP filings for this company. Most foreign listings report under international standards, which this does not read.

Tracked funds

Held by 2 of 46 tracked funds at the end of Q3 2026.

Last quarter: 2 bought new.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
GappedTape · 2026-11-10
+6.4%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-07
+9.6%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-06
-7.2%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ down on earningsTape · 2026-11-06
-7.2% on earnings 2026-11-05
No measurable effect: stocks behave like random ones over the next three sessions (665 cases over 44 nights).
Earnings date movedEvent · 2026-11-03
2026-11-05 -> 2026-11-09
No measurable effect: stocks behave like random ones over the next three sessions (2,989 cases over 51 nights).
Closed below its 20- and 50-day on heavy volumeTape · 2026-11-03
below 20d & 50d on 1.8x volume at 32.47
No measurable effect: stocks behave like random ones over the next three sessions (1,780 cases over 60 nights).
GappedTape · 2026-11-03
-10.6%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Unusual volumeTape · 2026-11-03
3.2 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Definium Therapeutics: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · 22 hours ago

Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.

Insiders
Bought on the open market
0
Sold on the open market
11
$5,640,649 total

Sold: Karlin Daniel, Barrow Robert, Wiley Matthew T., Sullivan Mark, Roberts Brandi.

Not counted above: 14 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-09-25 Karlin Daniel · Chief Medical Officer, Directorsell10,853$396,894
2026-09-25 Barrow Robert · Chief Executive Officer, Directorsell31,550$1,153,784
2026-09-25 Wiley Matthew T. · Chief Commercial Officersell3,097$113,257
2026-09-25 Sullivan Mark · Chief Legal Officersell14,051$513,845
2026-09-25 Roberts Brandi · Chief Financial Officersell3,377$123,497
2026-09-18 Vallone Carol A · Directoroption exercise1,086$38,575
2026-09-18 Krebs Andreas · Directoroption exercise1,629$57,862
2026-09-14 Karlin Daniel · Chief Medical Officeraward200,000

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What analysts expect
Strong buy5
Buy14
Hold0
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Definium Therapeutics, Inc. Common Shares (DFTX) — The Tape